NASDAQ:INCR InterCure (INCR) Stock Forecast, Price & News $1.65 -0.02 (-1.20%) (As of 09/20/2023 ET) Add Compare Share Share Today's Range$1.65▼$1.7050-Day Range$1.39▼$1.7252-Week Range$1.39▼$5.56Volume25,619 shsAverage Volume44,491 shsMarket CapitalizationN/AP/E Ratio12.69Dividend YieldN/APrice Target$5.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media InterCure MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside203.0% Upside$5.00 Price TargetShort InterestHealthy0.13% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.36 out of 5 stars 3.5 Analyst's Opinion Consensus RatingInterCure has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.00, InterCure has a forecasted upside of 203.0% from its current price of $1.65.Amount of Analyst CoverageInterCure has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.13% of the float of InterCure has been sold short.Short Interest Ratio / Days to CoverInterCure has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in InterCure has recently increased by 156.62%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldInterCure does not currently pay a dividend.Dividend GrowthInterCure does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for INCR. Previous Next 1.7 News and Social Media Coverage News SentimentInterCure has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.Search Interest2 people have searched for INCR on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows3 people have added InterCure to their MarketBeat watchlist in the last 30 days. Previous Next N/A Company Ownership Insider Buying vs. Insider SellingIn the past three months, InterCure insiders have not sold or bought any company stock. Previous Next 1.9 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of InterCure is 12.69, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 122.94.Price to Earnings Ratio vs. SectorThe P/E ratio of InterCure is 12.69, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 159.19.Price to Book Value per Share RatioInterCure has a P/B Ratio of 0.45. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About InterCure (NASDAQ:INCR) StockInterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.Read More INCR Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INCR Stock News HeadlinesSeptember 1, 2023 | benzinga.comCanndoc Reports Record Revenue Amid Cannabis Market TurmoilAugust 22, 2023 | theglobeandmail.comClosing Bell: Intercure Ltd up on Monday (INCR-U)September 21, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.August 19, 2023 | theglobeandmail.comul: Bottom 25 Performing Stocks Year-to-Date on TSX (INCR-U)August 3, 2023 | msn.comInterCure: Leader In Israel's Growing Medical Cannabis MarketJuly 23, 2023 | theglobeandmail.comIntercure: Top 10 Undervalued Micro Cap Stocks on TSX (INCR-U)July 10, 2023 | financialpost.comInterCure Ltd. Announces Proposed Voluntary Delisting from the Toronto Stock Exchange and shall continue to be listed on the NASDAQ and TASEMay 16, 2023 | finanznachrichten.deInterCure Ltd.: InterCure Announces Record Breaking First Quarter Revenues with 22% growth YOYSeptember 21, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.May 16, 2023 | msn.comInterCure Stock Trading Lower On Q1 Revenue Growth Of 22%, Here Are The DetailsMay 15, 2023 | benzinga.comInterCure Announces Record Breaking First Quarter Revenues with 22% growth YOYApril 27, 2023 | theglobeandmail.comClosing Bell: Intercure Ltd down on Monday (INCR-U)April 26, 2023 | theglobeandmail.comClosing Bell: Intercure Ltd flat on Monday (INCR-U)April 25, 2023 | finance.yahoo.comInterCure Informs That A Lawsuit Was Filed Against the Company by Minority Shareholders of Its SubsidiaryApril 24, 2023 | finance.yahoo.comInterCure Informs That An Application To Approve a Class Action Against 26 Cannabis Companies in Israel, Including InterCure, Was Filed to The Court In IsraelApril 20, 2023 | finance.yahoo.comInterCure Ltd. Partners with TYSON 2.0 in Israel, Australia, United Kingdom, Germany and Other EU CountriesApril 19, 2023 | theglobeandmail.comClosing Bell: Intercure Ltd flat on Friday (INCR-U)April 15, 2023 | theglobeandmail.comClosing Bell: Intercure Ltd down on Friday (INCR-U)April 11, 2023 | theglobeandmail.comClosing Bell: Intercure Ltd flat on Wednesday (INCR-U)April 8, 2023 | theglobeandmail.comClosing Bell: Intercure Ltd down on Wednesday (INCR-U)April 3, 2023 | finance.yahoo.comInterCure Reschedules 2022 Full Year Results Conference CallApril 3, 2023 | msn.comInterCure Shares Soar On FY22 Record Revenue Of $108.3MApril 1, 2023 | theglobeandmail.comClosing Bell: Intercure Ltd up on Thursday (INCR-U)March 31, 2023 | finance.yahoo.comInterCure Announces Record Fourth Quarter and Fiscal Year End 2022 ResultsMarch 30, 2023 | theglobeandmail.comIntercure: Bottom 25 Performing Stocks Year-to-Date on TSX (INCR-U)March 16, 2023 | money.usnews.comIntercure LtdFebruary 14, 2023 | msn.comInterCure Sues Cann Pharmaceuticals To Recover Funds Following Failed MergerSee More Headlines Receive INCR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for InterCure and its competitors with MarketBeat's FREE daily newsletter. Email Address INCR Company Calendar Today9/20/2023Next Earnings (Estimated)11/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Drug Manufacturers—Specialty & Generic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INCR CUSIPN/A CIK1857030 Webwww.intercure.co Phone972774605012FaxN/AEmployees370Year FoundedN/APrice Target and Rating Average Stock Price Forecast$5.00 High Stock Price Forecast$5.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+203.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$0.13 Trailing P/E Ratio12.69 Forward P/E RatioN/A P/E GrowthN/ANet Income$13.36 million Net Margins4.28% Pretax Margin6.32% Return on Equity3.37% Return on Assets1.98% Debt Debt-to-Equity Ratio0.20 Current Ratio1.90 Quick Ratio1.21 Sales & Book Value Annual Sales$115.83 million Price / SalesN/A Cash Flow$0.38 per share Price / Cash Flow4.31 Book Value$3.64 per share Price / Book0.45Miscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable Beta1.03 10 Best Stocks to Own in 2023Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2023 and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Alexander Rabinovitch (Age 52)CEO & Director Mr. Amos Cohen (Age 44)Chief Financial Officer Einat ZehaviVP of SalesMr. Rami Levy (Age 58)Chief Operating Officer of Canndoc Mr. Omri BatzirCorp. ControllerKey CompetitorsAptinyxNASDAQ:APTXGH ResearchNASDAQ:GHRSLAVA TherapeuticsNASDAQ:LVTXMorphoSysNASDAQ:MORNLS PharmaceuticsNASDAQ:NLSPView All CompetitorsInstitutional OwnershipCitadel Advisors LLCBought 900 shares on 8/15/2023Ownership: 0.000%Mirae Asset Global Investments Co. Ltd.Sold 158,452 shares on 8/10/2023Ownership: 1.204%Cambria Investment Management L.P.Bought 57,995 shares on 8/10/2023Ownership: 0.136%View All Institutional Transactions INCR Stock - Frequently Asked Questions Should I buy or sell InterCure stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for InterCure in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INCR shares. View INCR analyst ratings or view top-rated stocks. What is InterCure's stock price forecast for 2023? 1 Wall Street analysts have issued twelve-month price targets for InterCure's stock. Their INCR share price forecasts range from $5.00 to $5.00. On average, they anticipate the company's share price to reach $5.00 in the next twelve months. This suggests a possible upside of 203.0% from the stock's current price. View analysts price targets for INCR or view top-rated stocks among Wall Street analysts. How have INCR shares performed in 2023? InterCure's stock was trading at $3.30 at the beginning of the year. Since then, INCR stock has decreased by 50.0% and is now trading at $1.65. View the best growth stocks for 2023 here. Are investors shorting InterCure? InterCure saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 34,900 shares, an increase of 156.6% from the August 15th total of 13,600 shares. Based on an average daily volume of 46,500 shares, the short-interest ratio is presently 0.8 days. Currently, 0.1% of the company's shares are short sold. View InterCure's Short Interest. When is InterCure's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 21st 2023. View our INCR earnings forecast. What is InterCure's stock symbol? InterCure trades on the NASDAQ under the ticker symbol "INCR." Who are InterCure's major shareholders? InterCure's stock is owned by many different institutional and retail investors. Top institutional shareholders include Mirae Asset Global Investments Co. Ltd. (1.20%), Cambria Investment Management L.P. (0.14%) and Citadel Advisors LLC (0.00%). How do I buy shares of InterCure? Shares of INCR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is InterCure's stock price today? One share of INCR stock can currently be purchased for approximately $1.65. How many employees does InterCure have? The company employs 370 workers across the globe. How can I contact InterCure? The official website for the company is www.intercure.co. The company can be reached via phone at 972774605012. This page (NASDAQ:INCR) was last updated on 9/21/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InterCure Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.